
Nguyen Thu Yen, Mark R. Duffy, Nguyen Minh Hong, Nguyen Tran Hien, Marc Fischer, and Susan L. Hills*
Department of Epidemiology, National Institute of Hygiene and Epidemiology, Hanoi, Vietnam; Arboviral Diseases Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado; Expanded Program on Immunization, National Institute of Hygiene and Epidemiology, Hanoi, Vietnam

Abstract. Japanese encephalitis (JE) is recognized as an important public health problem in Vietnam. A JE immunization program was introduced in 1997 in high-risk districts and expanded to additional districts over subsequent years. We reviewed national acute encephalitis syndrome (AES) surveillance data for 1998–2007 and analyzed more detailed data regarding JE from five northern provinces in 2004 and 2005. The annual reported incidence of AES in Vietnam ranged from 3.0 to 1.4 cases per 100,000 population with a decreasing trend over the 10-year period. The mean annual incidence of AES was highest in the northern region of the country. Of 421 AES cases from five northern provinces with laboratory results reported, 217 (52%) had laboratory evidence of recent JEV infection. As Vietnam moves closer to control of JE through immunization, accurate JE surveillance data will be important to evaluate and guide the program.

METHODS

In the national surveillance system in Vietnam, a case of AES, called viral encephalitis for reporting purposes, is defined as a patient with fever (> 38°C) and change in mental status, abnormal movements, seizure, tremor, or spastic paralysis. A case of JE is defined as a case of AES with IgM against JEV in serum or cerebrospinal fluid. IgM was detected by using the National Institute of Hygiene and Epidemiology (NIHE) in-house JEV enzyme-linked immunosorbent assay (ELISA).

Vietnam is divided into four disease surveillance reporting regions: northern, central, highlands, and southern. The number of AES cases and deaths identified at district health centers are reported to provincial health authorities each week and to regional surveillance centers once a month. Regional surveillance centers provide the number of AES cases and deaths per province to NIHE annually. No additional patient information is included in the national AES surveillance data.

In 1997, a domestically produced, inactivated mouse brain-derived JE vaccine was introduced into the expanded program on immunization for children 1–5 years of age in 12 high-risk districts in 1997. The program was subsequently expanded, initially to other high-risk districts in the northern region, in 2001 to selected districts in the central region, and then to other parts of the country. By 2007, JE vaccine was being administered through the national immunization program to children in 437 (65%) of 676 districts in Vietnam. The program is conducted through annual campaigns, with two primary vaccine doses delivered 1–2 weeks apart, and a booster dose is given one year later. Additional children in Vietnam were vaccinated with privately purchased JE vaccine; this was domestically produced or imported inactivated, mouse brain-derived vaccine.

Since the introduction of JE vaccine, there is limited information in the English literature on the incidence of AES in Vietnam or the proportion of AES that is caused by JE. We report the epidemiology of AES and JE in Vietnam during 1998–2007 based on analysis of available surveillance data.
RESULTS

AES in Vietnam. A total of 19,354 AES cases and 741 AES deaths were reported in Vietnam during 1998–2007. The mean annual number of AES cases was 1,935; the highest number of cases was reported in 2004 (n = 2,286) and the lowest number of cases was reported in 2007 (n = 1,208). The mean annual incidence was 2.4 (range = 1.4–3.0) cases per 100,000 population (Figure 2). Overall, there was a decreasing trend in incidence over the 10-year period ($P < 0.01$). The case-fatality rate of all AES cases in the period was 3.8%, with no significant change over time.

The northern region had the highest mean annual incidence rate during the 10-year period (3.0 cases per 100,000), and the highlands region had the lowest incidence rate (1.3 cases per 100,000) (Table 1). There was moderate variability in annual incidence rates within all four regions, with a significant decreasing trend in incidence during the 10-year period in the northern, central, and southern regions ($P < 0.01$), but not in the highlands region.

Among the 64 provinces, seven (11%) reported a mean annual incidence rate of $\geq 6.0$ cases per 100,000 population: three in the northwest of the country (Lai Chau, Son La, and Dien Bien), two in the northeast of the country (Bac Giang and Lang Son), and two in the south of the country (Binh Duong and Bac Lieu) (Figure 3). A significant decreasing trend in incidence occurred in 33 (52%) provinces, a significant increasing trend occurred in 13 (20%) provinces, and no significant change occurred in 18 (28%) provinces.

![Figure 1: Map of northern Vietnam showing five provinces that collected additional information and conducted Japanese encephalitis virus testing in 2004–2005.](image1)

![Figure 2: Annual acute encephalitis syndrome incidence rate in Vietnam, 1998–2007. The decreasing trend in incidence was significant ($P < 0.01$).](image2)

![Figure 3: Mean annual incidence of acute encephalitis syndrome by province, Vietnam, 1998–2007.](image3)

<table>
<thead>
<tr>
<th>Region</th>
<th>No. provinces</th>
<th>AES cases per year Mean</th>
<th>Range (per 100,000 population)</th>
<th>AES incidence per year Mean</th>
<th>Range</th>
<th>AES case fatality rate, % Mean</th>
</tr>
</thead>
<tbody>
<tr>
<td>Northern</td>
<td>29</td>
<td>1,080</td>
<td>697–1,364</td>
<td>3.0</td>
<td>1.8–3.7</td>
<td>2.7</td>
</tr>
<tr>
<td>Central</td>
<td>11</td>
<td>254</td>
<td>80–404</td>
<td>2.3</td>
<td>0.7–3.6</td>
<td>2.0</td>
</tr>
<tr>
<td>Highlands</td>
<td>4</td>
<td>44</td>
<td>6–98</td>
<td>1.3</td>
<td>0.2–2.9</td>
<td>7.9</td>
</tr>
<tr>
<td>Southern</td>
<td>20</td>
<td>558</td>
<td>420–655</td>
<td>1.9</td>
<td>1.4–2.4</td>
<td>6.4</td>
</tr>
<tr>
<td>All regions</td>
<td>64</td>
<td>1,935</td>
<td>1,208–2,286</td>
<td>2.4</td>
<td>1.4–3.0</td>
<td>3.8</td>
</tr>
</tbody>
</table>

* AES = acute encephalitis syndrome.
† Prior to 2004, there were 61 provinces in Vietnam: 28 in the northern region, 11 in the central region, 3 in the highlands region, and 19 in the southern region.
Overall, reported AES cases in Vietnam peaked during the summer months. However, this seasonal pattern was primarily seen in the northern region where 7,886 (73%) of 10,797 cases occurred from May through September. In the other three regions, cases were more evenly distributed through the year (Figure 4).

**JE in five northern provinces of Vietnam.** The five provinces in the northern surveillance region with additional JE-specific data available reported 705 AES cases in 2004 and 2005. Among these cases, JEV IgM ELISA was performed for 421 (60%) and 217 (52%) were positive. The proportion of AES cases with laboratory evidence of JE ranged from 8 (17%) of 47 in Bac Giang Province to 76 (71%) of 107 in Thai Binh Province (Table 2). Among 217 JE-positive patients, 198 (91%) were ≤ 15 years of age, including 6 (3%) children < 1 year of age, 47 (22%) children 1–5 years of age, 68 (31%) children 6–10 years of age, and 77 (35%) children 11–15 years of age. The proportion of AES cases that were positive for JE was significantly higher among children 6–15 years of age compared with children ≤ 5 years of age and adults > 15 years of age (P < 0.01) (Table 3).

Of the sixty-one (28%) cases with known JE vaccination status, 11 (18%) were age-appropriately vaccinated with two or more doses of JE vaccine. Discharge status was collected consistently only from the patients in Hai Duong Province; 4 (12%) of 33 JE patients died and 8 (28%) of the survivors had significant sequelae.

**DISCUSSION**

The reported incidence of encephalitis in Vietnam showed a slightly decreasing trend during the 10 years from 1998 through 2007. In addition, no epidemics occurred, unlike the pattern in the decades prior to vaccine introduction.3,6,8 The northern region of the country continued to demonstrate the highest incidence of encephalitis, as in previous years.6 However, during 1998–2007, the highest province-specific incidence rates for encephalitis occurred in the far northwestern and northeastern areas, in contrast to the pattern reported in the late 1980s and early 1990s when highest rates occurred in the Red River delta area. This change may reflect the impact of the JE immunization program, which had an early focus on districts in this delta area.

![Figure 4](image-url)  
**Figure 4.** Acute encephalitis syndrome cases by month and reporting region, Vietnam, 1998–2007 (n = 19,354).

<table>
<thead>
<tr>
<th>Province</th>
<th>No. (%) of AES cases tested for JEV IgM among all AES cases</th>
<th>No. (%) of JEV IgM-positive cases among AES cases tested</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thai Binh</td>
<td>107/184 (58)</td>
<td>76/107 (71)</td>
</tr>
<tr>
<td>Hai Phong</td>
<td>49/106 (46)</td>
<td>30/49 (61)</td>
</tr>
<tr>
<td>Thanh Hoa</td>
<td>114/161 (71)</td>
<td>70/114 (61)</td>
</tr>
<tr>
<td>Hai Duong</td>
<td>104/122 (85)</td>
<td>33/104 (32)</td>
</tr>
<tr>
<td>Bac Giang†</td>
<td>47/132 (36)</td>
<td>8/47 (17)</td>
</tr>
<tr>
<td>Total</td>
<td>421/705 (60)</td>
<td>217/421 (52)</td>
</tr>
</tbody>
</table>

* AES = acute encephalitis syndrome; JEV = Japanese encephalitis virus.  
† Data from 2004 only.

A 1995 study found 33 (42%) of 79 AES patients admitted to Bach Mai Hospital in Hanoi during two months of summer had evidence of acute JE infection, including 31 (67%) of 46 children < 18 years of age.9 Among 1,121 AES encephalitis patients admitted to hospitals in Hanoi in 1992–1993, 716 (64%) were JE positive.6 Our findings of 52% JE-positive patients among 421 AES patients, including 55% JE-positive patients among children ≤ 15 years of age, from five provinces of the northern surveillance region in 2004–2005 are similar to these results. However, we found the proportion of JE cases among AES patients varied from 17% (8 of 47) in Bac Giang Province to 71% (76 of 107) in Thai Binh Province. This finding may indicate that a substantial proportion of AES in Vietnam continues to be attributable to JE, but the proportion likely varies from province to province. Information was not available on the timing of sample collection or the number of cases with a sample collected at least 10 days after onset when antibodies are reliably detectable.2 We do not know how any differences between provinces in timing of sample collection may have affected results overall or the differences in case positivity rates between provinces.

In the 10 years after introduction of the JE immunization program, a small decrease in AES incidence occurred. However, for a number of reasons, it is difficult to clearly define the impact of the program. The program is specific for children 1–5 years of age but the national surveillance system does not collect age-related data. Vaccination against JE is instituted on a district-by-district basis, but AES incidence rate by district is not readily available. Changes in AES incidence rates could be attributable to increases or decreases in the incidence of either JE or other causes of AES. If data are aggregated, a decrease in incidence in one area subsequent to vaccination may not be evident if a concurrent increase in incidence occurred in another area. The intensity of JEV transmission varies from year to year, and this variability is difficult to take into account. Finally, knowledge of vaccine coverage is important to under-
stand expected impact; although high coverage rates > 90% are reported in the districts where the national program has been implemented (Yen N.T., unpublished data), the percentage of the population additionally protected through private purchase of vaccine is unknown.

To better understand the epidemiology of JE in Vietnam, surveillance should be enhanced by collection of additional epidemiologic information from cases, and expansion of JE testing. One strategy to achieve this could be case-based investigations at a number of sentinel sites in different regions of the country. Enhanced surveillance and JE testing will also provide data necessary to assess the effectiveness of the JE vaccination program, and determine whether refinements in strategy, such as broadening the target age group for vaccination, are needed. As JE control improves, it will also be important to consider other etiologies of AES, which will increasingly represent a larger proportion of AES cases. Access to testing for other vaccine-preventable or treatable causes of AES will be particularly important.

There are several limitations of this evaluation. First, available data included only AES morbidity and mortality by province at a national level, and JE-specific data from a limited number of provinces. Although there were no evident changes in healthcare access or reporting practices during the surveillance period, any changes could have affected results. Finally, the provinces where laboratory testing was conducted were not a representative sample of all provinces in Vietnam, and the proportion of laboratory-confirmed JE cases among AES cases cannot be extrapolated to estimate the proportion of AES caused by JEV in Vietnam as a whole. Despite these limitations we believe that the data in this report suggest that JE vaccination in Vietnam might be resulting in a trend towards decreased incidence of JE among children.

Because JE is recognized as a serious public health problem in Vietnam, the government plans to expand the JE immunization program nationwide by 2011. Data from the surveillance system have been useful to identify priority areas for vaccine introduction as the program has expanded since 1997. As Vietnam moves closer to control of JE, a strengthened surveillance system will be important to carefully evaluate and guide the control program.

Received May 7, 2010. Accepted for publication June 17, 2010.

Acknowledgments: We thank Jennifer Lehman for mapping assistance and Nicole Lindsey for statistical support.

Financial support: This study was supported in part by a grant from the Centers for Disease Control and Prevention Global Diseases Detection Project.

Authors’ addresses: Nguyen Thu Yen and Nguyen Minh Hong, Department of Epidemiology, National Institute of Hygiene and Epidemiology, Hanoi, Vietnam, E-mails: yentc2004@gmail.com and hongnihe@gmail.com. Mark R. Duffy, Marc Fischer, and Susan L. Hills, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO, E-mails: mark.duffy@brooks.af.mil, mfischer@cdc.gov, and shills@cdc.gov. Nguyen Tran Hien, Expanded Program on Immunization, National Institute of Hygiene and Epidemiology, Hanoi, Vietnam, E-mail: nthiennihe@vnn.vn.

REFERENCES